查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1912609

按产品类型、材质、应用、最终用户和分销管道分類的黏性注射器市场—2026-2032年全球预测

Bonded Syringe Market by Product Type, Material, Application, End User, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，黏合注射器市场价值将达到 8.3527 亿美元，到 2026 年将成长至 8.9628 亿美元，到 2032 年将达到 14.8027 亿美元，复合年增长率为 8.51%。

关键市场统计数据
基准年 2025 8.3527亿美元
预计年份：2026年 8.9628亿美元
预测年份 2032 1,480,270,000 美元
复合年增长率 (%) 8.51%

对黏合注射器市场进行全面概述，重点关注安全性、製造创新、监管要求和供应链韧性。

黏合注射器产业正处于临床需求、安全法规和製造创新三者交汇发展的阶段。对安全注射技术的日益重视，以及疫苗接种计划和慢性病管理的不断扩展，促使人们更加关注能够提高无菌性、给药精度和使用者安全性的注射器设计特性。同时，材料科学和组装流程的进步正在改变成本结构，并催生出新型预灌封和安全型注射器，以满足医护人员和患者的需求。

以安全为导向的产品演进、数位化可追溯性和地理分散式製造如何重塑竞争格局和品质预期

组合注射器的市场格局正经历着变革性的转变，这主要得益于技术、临床和政策的共同发展。首先，随着医疗系统将减少针刺伤和用药错误列为优先事项，安全设计和预灌封包装已从小众应用领域走向主流采购清单。聚合物工程和玻璃加工技术的逐步进步推动了这一转变，这些进步实现了安全密封、精准给药以及与针头安全功能的整合。

检验了截至2025年美国关税对注射器价值链筹资策略、成本动态和供应链韧性的累积影响。

美国在2025年前实施的关税和贸易政策调整，对保税注射器供应链产生了显着的累积影响，波及采购决策、成本结构和供应商策略。关税导致的投入成本上涨，使得玻璃和塑胶组件的到岸成本上升，迫使买家重新评估长期合同，并推动更透明的成本转嫁机制。为此，许多製造商正在加快供应商多元化和本土化生产，以降低进口关税和物流波动带来的风险。

可操作的细分资讯揭示了产品类型、应用、终端用户通路、通路和材料选择如何共同驱动差异化需求和策略。

細項分析揭示了因产品形式、临床用途、终端用户环境、通路和材料选择而异的细微机会和限制因素。依产品类型划分，市场包括一次性注射器、传统注射器、预灌封注射器和安全注射器，其中安全注射器可进一步细分为玻璃和塑胶材质。这些差异至关重要，因为玻璃和聚合物预灌封注射器在器械设计、灭菌途径以及与特定治疗方法的兼容性方面存在显着差异。

区域趋势分析：美洲、欧洲、中东和非洲以及亚太地区的趋势对产能决策、合规策略和分销模式的影响

区域趋势显着影响绝缘注射器市场的製造地选择、监管合规负担和分销复杂性。在美洲，采购趋势强调韧性、监管可追溯性以及透过强大的低温运输和库存管理系统来支持大规模疫苗宣传活动的能力。该地区的公共和私人买家通常要求供应商进行风险评估、提供品质认证并保证可靠的前置作业时间，这影响着製造商如何优先考虑区域生产能力。

竞争对手和供应商生态系统洞察凸显了无菌生产规模、监管准备和创新管道如何决定竞争优势。

主要企业与新兴企业之间的竞争动态集中在预填充剂型的大规模无菌生产能力、法规遵循、安全性和产品创新。老牌製造商致力于提升密封完整性和自动化组装流程等渐进式技术改进，而新参与企业则专注于透过增强安全性和采用永续性材料等方式在细分市场中脱颖而出。医疗设备製造商与製药公司在预填充给药系统领域的合作日益增多，反映出生物製药和自我给药疗法的日益普及。

产业领导者可以采取切实可行的营运、监管和商业性措施，以增强供应链韧性、加速创新并满足买家预期

产业领导者应在业务营运、产品策略和商业性合作等方面采取果断行动，抓住近期机会并建立永续的韧性。首先，应优先考虑双源采购和区域产能策略，以降低关税风险并缩短前置作业时间，同时协商合约条款，以分担供应链各环节的风险。其次，应投资模组化生产线和检验的自动化技术，以实现玻璃和塑胶预灌装规格之间的快速切换，并能灵活应对需求波动。

我们严谨的混合方法研究途径结合了高阶主管访谈、监管分析、专利和临床文献审查以及情境检验，以确保获得可靠的见解。

本分析结合了第一手和第二手研究资料，以确保其可靠性、检验和实用性。第一手研究包括对采购主管、医院供应链经理、契约製造主管和监管事务专家的访谈，以了解当前的业务重点和决策驱动因素。第二手研究涵盖了监管指导文件、关于製造最佳实践的白皮书、医疗设备创新专利申请以及探讨安全性和可用性设计考虑的同行评审临床文献。

总之，综合分析表明，营运柔软性、严格的监管合规性和以客户为中心的创新对于确保在註射器生态系统中保持可持续的主导地位至关重要。

总之，黏合注射器产业正处于一个转折点，产品安全性、供应链韧性和监管审查三者相互交织，重新定义了竞争优势。那些积极平衡生产柔软性与严格品管，并提供可追溯性和以服务为导向的商业模式的製造商和供应商，将获得可持续的竞争优势。采购经理应预期，市场将继续关注区域生产能力、检验的多源采购策略以及价值链风险共用的合约机制。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 按产品类型分類的黏合剂注射器市场

  • 自动丢弃注射器
  • 普通注射器
  • 预灌封注射器

第九章 黏合剂注射器市场：依材料分类

  • 玻璃
  • 塑胶

第十章 黏合剂注射器市场：依应用领域划分

  • 药物输送
  • 胰岛素给药
  • 疫苗接种
    • 成人疫苗接种
    • 儿童疫苗接种

第十一章 以最终用户分類的黏合剂注射器市场

  • 门诊手术中心
  • 诊所
  • 居家医疗
  • 医院
    • 私立医院
    • 公立医院

第十二章 按分销管道分類的黏合剂注射器市场

  • 医院药房
  • 网路药房
  • 零售药房

第十三章 黏性注射器市场：按地区划分

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章 按组别分類的黏合剂注射器市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章 各国黏性注射器市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章美国黏合剂注射器市场

第十七章 中国医用黏胶注射器市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Credence MedSystems, Inc.
  • DMC Medical Limited
  • Gerresheimer AG
  • Henke-Sass, Wolf GmbH
  • Hindustan Syringes & Medical Devices Ltd
  • Nipro Corporation
  • SCHOTT AG
  • Smiths Medical, Inc.
  • Terumo Corporation
  • West Pharmaceutical Services, Inc.
  • Ypsomed Holding AG
Product Code: MRR-AE420CB13A5B

The Bonded Syringe Market was valued at USD 835.27 million in 2025 and is projected to grow to USD 896.28 million in 2026, with a CAGR of 8.51%, reaching USD 1,480.27 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 835.27 million
Estimated Year [2026] USD 896.28 million
Forecast Year [2032] USD 1,480.27 million
CAGR (%) 8.51%

A comprehensive orientation to the bonded syringe landscape emphasizing safety, manufacturing innovation, regulatory expectations, and supply chain resilience

The bonded syringe sector is evolving at the intersection of clinical demand, safety regulation, and manufacturing innovation. Increasing emphasis on safe injection practices, combined with expanded vaccination programs and chronic disease management, has intensified attention on syringe design features that improve sterility, dosing accuracy, and user safety. Concurrently, material science advances and automation in assembly are reshaping cost structures and enabling new prefillable and safety-enabled formats that respond to clinician and patient needs.

Regulatory agencies worldwide have tightened expectations around device safety and supply transparency, creating higher compliance thresholds for manufacturing and post-market surveillance. These pressures are prompting forward-looking manufacturers to integrate traceability features, enhanced sterilization validation, and design-for-assembly approaches early in development. At the same time, healthcare providers are demanding more resilient supply chains and product consistency, particularly for high-volume items used across vaccination, insulin administration, and hospital settings.

As a result, stakeholders across the value chain-from raw material suppliers and component manufacturers to distributors and large institutional purchasers-are rethinking partnerships, vertical integration options, and inventory strategies. This introduction frames the broader forces that shape competitive positioning, R&D prioritization, and procurement strategy within the bonded syringe ecosystem, establishing context for the deeper analysis that follows.

How safety-driven product evolution, digitized traceability, and regionalized manufacturing are reshaping competitive dynamics and quality expectations

The bonded syringe landscape is undergoing transformative shifts driven by converging technological, clinical, and policy developments. Firstly, safety-engineered designs and prefillable formats have migrated from niche applications to mainstream procurement lists as healthcare systems prioritize reducing needlestick injuries and medication errors. This transition is supported by incremental advances in polymer engineering and glass processing that enable reliable sealing, precise dosing, and integration with needle safety mechanisms.

Secondly, digitization is emerging around product traceability and cold-chain monitoring, enabling better end-to-end visibility for high-value injectable therapies. Connected packaging concepts and serialization are increasingly discussed as part of risk mitigation and accountability frameworks, especially for mass vaccination campaigns. Thirdly, regulatory harmonization efforts in key jurisdictions are tightening requirements for post-market surveillance and component provenance, accelerating supplier audits and qualification rigor.

Finally, manufacturing models are shifting toward regionalization to reduce lead times and tariff exposure, while contract manufacturers invest in cleanroom automation and validated assembly lines capable of handling both glass and plastic prefillable formats. Together, these shifts are altering competitive dynamics, raising the bar for quality assurance, and creating opportunities for manufacturers that can combine robust regulatory compliance with flexible, cost-efficient production.

Examining the cumulative impact of United States tariff measures through 2025 on sourcing strategies, cost dynamics, and supply chain resilience across the syringe value chain

The imposition of tariffs and trade policy adjustments in the United States through 2025 has created a material cumulative effect across the bonded syringe supply chain, influencing sourcing decisions, cost structures, and supplier strategies. Tariff-driven input cost increases have translated into higher landed costs for both glass and plastic components, prompting buyers to re-evaluate long-term contracts and push for more transparent cost pass-through mechanisms. In response, many manufacturers have accelerated supplier diversification and onshoring initiatives to mitigate exposure to import levies and logistical volatility.

These shifts have also intensified emphasis on total landed cost analysis rather than unit price alone. Procurement teams now place greater weight on lead time reliability, inventory carrying costs, and the flexibility to scale production in response to demand surges. For some suppliers, the tariff environment has driven consolidation as smaller providers struggle with compressed margins and increased compliance costs; conversely, vertically integrated manufacturers have leveraged scale to absorb cost pressures while maintaining service levels.

Moreover, tariffs have encouraged investment in regional manufacturing capacity to serve large institutional buyers more directly, supporting faster replenishment cycles and tighter quality oversight. Consequently, strategic players are prioritizing resilience - reconfiguring supply networks, locking in secure raw material flows, and enhancing contractual terms to include contingency arrangements that reduce disruption risk.

Actionable segmentation intelligence revealing how product type, application, end-user channels, distribution pathways, and material choices together drive differentiated demand and strategy

Segmentation analysis reveals nuanced opportunities and constraints that vary by product form, clinical use, end-user setting, distribution pathway, and material selection. Based on Product Type, the market encompasses Auto-Disable Syringe, Conventional Syringe, Prefillable Syringe, and Safety Syringe, with the Prefillable Syringe further differentiated between Glass and Plastic formats. These distinctions matter because device design, sterilization pathways, and compatibility with specific therapies differ substantially between glass and polymer prefillable options.

Based on Application, the bonded syringe ecosystem serves Drug Delivery, Insulin Delivery, and Vaccination, with Vaccination subdivided into Adult Immunization and Pediatric Immunization, each segment presenting unique cold-chain and dosing considerations. Based on End User, demand streams originate from Ambulatory Surgical Centers, Clinics, Home Care, and Hospitals, where Hospitals further bifurcate into Private Hospitals and Public Hospitals, reflecting divergent procurement cycles, tendering behaviors, and margin sensitivities. Based on Distribution Channel, products flow through Direct Tender, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies, while Online Pharmacies are further categorized into Direct To Consumer and Wholesale E-Channels, indicating growing e-commerce influence on last-mile delivery and consumer choice. Based on Material, the market is also studied across Glass and Plastic compositions, an axis that directly informs sterilization compatibility, environmental considerations, and breakage risk.

Taken together, these segmentation lenses highlight that competitive positioning must be multidimensional: product innovation should align with application clinical requirements, distribution strategies must reflect end-user purchasing behavior, and material decisions need to reconcile performance with cost and sustainability goals. Strategic portfolio decisions informed by this segmentation will favor modular platforms and adaptable supply arrangements that can be tuned to the distinct needs of each channel and clinical use case.

Regional intelligence showing how Americas, Europe Middle East & Africa, and Asia-Pacific dynamics shape capacity decisions, compliance tactics, and distribution models

Regional dynamics significantly influence manufacturing location choices, regulatory compliance burdens, and distribution complexity across the bonded syringe landscape. In the Americas, procurement trends emphasize resilience, regulatory traceability, and the ability to support large-scale vaccination campaigns with robust cold-chain and inventory systems. Private and public institutional buyers in this region often require supplier risk assessments, quality certifications, and reliable lead times, shaping how manufacturers prioritize regional capacity.

In Europe, Middle East & Africa, regulatory harmonization initiatives coexist with variable procurement capabilities across countries, producing a patchwork of requirements that suppliers must navigate through localized compliance strategies and flexible distribution networks. This region values sustainability credentials and increasingly rigorous post-market surveillance mechanisms, which inform product design choices and materials selection.

In Asia-Pacific, high-volume production capacity and rapidly growing healthcare access create both competitive manufacturing advantages and intense local demand. Manufacturers in this region are investing in automation and quality management to meet export standards while also servicing robust domestic vaccination and insulin delivery needs. Across all three regions, the balance between centralized manufacturing efficiency and local responsiveness continues to drive strategic investment decisions, supplier partnerships, and distribution models that align with regional policy, clinical practice, and procurement behavior.

Competitor and supplier ecosystem insights highlighting how sterile manufacturing scale, regulatory readiness, and innovation pipelines determine competitive advantage

Competitive dynamics among leading and emerging companies center on capabilities in high-volume sterile manufacturing, regulatory compliance, and product innovation for safety and prefilled formats. Established manufacturers are pursuing incremental engineering improvements, such as enhanced seal integrity and automated assembly processes, while new entrants focus on niche differentiation through safety-enabled features or sustainability-focused materials. Partnerships between device makers and pharmaceutical firms for prefilled drug delivery systems are growing, reflecting the increasing prevalence of biologics and self-administered therapies.

Market leaders are investing in expanded sterilization capacity, serialization, and digital quality systems to provide customers with audit-ready supply chains and predictable batch release timelines. Meanwhile, contract manufacturing organizations that can flex production across glass and polymer prefillable formats are seeing demand from brands seeking to reduce capital expenditure and accelerate time to market. Supplier ecosystems are also evolving to prioritize validated raw material sources and multi-sourcing strategies to reduce single-point-of-failure risks.

Collectively, these company-level trends indicate that competitive advantage will accrue to organizations that combine certified cleanroom infrastructure, robust regulatory affairs teams, and agile product development pipelines capable of responding to shifts in application mix, such as the rising share of self-administered chronic therapies.

Practical operational, regulatory, and commercial actions industry leaders can implement to strengthen supply resilience, accelerate innovation, and align with buyer expectations

Industry leaders should act decisively across operations, product strategy, and commercial engagement to capture near-term opportunities and build durable resilience. First, prioritize dual-sourcing and regional capacity strategies to reduce tariff exposure and compress lead times, while negotiating contractual clauses that share risk across the supply chain. Second, invest in modular manufacturing lines and validated automation that permit rapid conversion between glass and plastic prefillable formats and enable scalable responses to demand variability.

Third, deepen collaboration with healthcare purchasers by offering value-added services such as end-to-end traceability data, clinician training modules on safety devices, and inventory-as-a-service models that reduce hospital stockouts and overall system waste. Fourth, enhance regulatory and quality systems to expedite customer audits and support cross-border market entry, with particular attention to serialization and post-market surveillance capabilities. Fifth, integrate sustainability metrics into product roadmaps and supplier evaluations to meet evolving buyer expectations and regulatory pressures.

Finally, align commercial models with digital distribution trends by developing e-commerce readiness for direct-to-consumer channels and building analytics capabilities to track demand signals. Combined, these actions will strengthen competitive positioning while reducing exposure to trade and supply disruptions.

A rigorous mixed-methods research approach combining executive interviews, regulatory analysis, patent and clinical literature review, and scenario validation to ensure dependable insights

This analysis synthesizes primary and secondary research streams designed to ensure reliability, triangulation, and practical relevance. Primary inputs include interviews with procurement leaders, hospital supply chain managers, contract manufacturing executives, and regulatory affairs specialists to capture current operational priorities and decision drivers. Secondary inputs encompass regulatory guidance documents, manufacturing best-practice white papers, patent filings for device innovations, and peer-reviewed clinical literature that informs safety and usability design considerations.

Data validation involved cross-referencing qualitative insights with observable industry behavior such as announced capacity investments, procurement tender terms, and supplier certification records. Where possible, historical shipment and trade patterns were examined to understand sourcing trends and the logistics impact of tariff changes. Analysts also applied scenario analysis to test the sensitivity of supplier networks to disruptive events and policy shifts, producing actionable implications for procurement and manufacturing strategies.

Throughout, methodological rigor was maintained by documenting interview protocols, coding qualitative responses for thematic consistency, and applying conservative interpretation rules to avoid overstating trends. This multi-layered approach ensures the findings are grounded in practitioner experience and corroborated by verifiable industry indicators.

Concluding synthesis emphasizing the imperative for operational flexibility, regulatory rigor, and customer-centric innovation to secure durable advantage in the syringe ecosystem

In conclusion, the bonded syringe landscape is at an inflection point where safety-driven product evolution, supply chain resilience, and regulatory scrutiny converge to redefine competitive success. Manufacturers and suppliers that proactively align manufacturing flexibility with stringent quality management, and that offer traceability and service-oriented commercial models, will find durable advantage. Procurement leaders should expect continued emphasis on regional capacity, validated multi-sourcing, and contractual mechanisms that share risks across the value chain.

The combined pressures of material selection, application-specific requirements, and distribution channel evolution mean that strategic portfolios must be nimble enough to support both institutionally procured volumes and growing direct-to-consumer pathways. By prioritizing investments in automation, serialization, and regulatory readiness, stakeholders can reduce vulnerability to trade shocks and accelerate time to market for differentiated prefillable and safety-enabled offerings. The path forward rewards those who balance operational rigor with customer-centric innovation, enabling more reliable, safer injection delivery for diverse clinical settings.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Bonded Syringe Market, by Product Type

  • 8.1. Auto-Disable Syringe
  • 8.2. Conventional Syringe
  • 8.3. Prefillable Syringe

9. Bonded Syringe Market, by Material

  • 9.1. Glass
  • 9.2. Plastic

10. Bonded Syringe Market, by Application

  • 10.1. Drug Delivery
  • 10.2. Insulin Delivery
  • 10.3. Vaccination
    • 10.3.1. Adult Immunization
    • 10.3.2. Pediatric Immunization

11. Bonded Syringe Market, by End User

  • 11.1. Ambulatory Surgical Centers
  • 11.2. Clinics
  • 11.3. Home Care
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Bonded Syringe Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Bonded Syringe Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Bonded Syringe Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Bonded Syringe Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Bonded Syringe Market

17. China Bonded Syringe Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. B. Braun Melsungen AG
  • 18.6. Becton, Dickinson and Company
  • 18.7. Credence MedSystems, Inc.
  • 18.8. DMC Medical Limited
  • 18.9. Gerresheimer AG
  • 18.10. Henke-Sass, Wolf GmbH
  • 18.11. Hindustan Syringes & Medical Devices Ltd
  • 18.12. Nipro Corporation
  • 18.13. SCHOTT AG
  • 18.14. Smiths Medical, Inc.
  • 18.15. Terumo Corporation
  • 18.16. West Pharmaceutical Services, Inc.
  • 18.17. Ypsomed Holding AG

LIST OF FIGURES

  • FIGURE 1. GLOBAL BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BONDED SYRINGE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BONDED SYRINGE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BONDED SYRINGE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BONDED SYRINGE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BONDED SYRINGE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BONDED SYRINGE MARKET SIZE, BY AUTO-DISABLE SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BONDED SYRINGE MARKET SIZE, BY AUTO-DISABLE SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BONDED SYRINGE MARKET SIZE, BY AUTO-DISABLE SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BONDED SYRINGE MARKET SIZE, BY CONVENTIONAL SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BONDED SYRINGE MARKET SIZE, BY CONVENTIONAL SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BONDED SYRINGE MARKET SIZE, BY CONVENTIONAL SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BONDED SYRINGE MARKET SIZE, BY PREFILLABLE SYRINGE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BONDED SYRINGE MARKET SIZE, BY PREFILLABLE SYRINGE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BONDED SYRINGE MARKET SIZE, BY PREFILLABLE SYRINGE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BONDED SYRINGE MARKET SIZE, BY GLASS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BONDED SYRINGE MARKET SIZE, BY GLASS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BONDED SYRINGE MARKET SIZE, BY GLASS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BONDED SYRINGE MARKET SIZE, BY PLASTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BONDED SYRINGE MARKET SIZE, BY PLASTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BONDED SYRINGE MARKET SIZE, BY PLASTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BONDED SYRINGE MARKET SIZE, BY DRUG DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BONDED SYRINGE MARKET SIZE, BY DRUG DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BONDED SYRINGE MARKET SIZE, BY DRUG DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BONDED SYRINGE MARKET SIZE, BY INSULIN DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BONDED SYRINGE MARKET SIZE, BY INSULIN DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BONDED SYRINGE MARKET SIZE, BY INSULIN DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BONDED SYRINGE MARKET SIZE, BY VACCINATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BONDED SYRINGE MARKET SIZE, BY VACCINATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BONDED SYRINGE MARKET SIZE, BY VACCINATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BONDED SYRINGE MARKET SIZE, BY ADULT IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BONDED SYRINGE MARKET SIZE, BY ADULT IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BONDED SYRINGE MARKET SIZE, BY ADULT IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BONDED SYRINGE MARKET SIZE, BY PEDIATRIC IMMUNIZATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BONDED SYRINGE MARKET SIZE, BY PEDIATRIC IMMUNIZATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BONDED SYRINGE MARKET SIZE, BY PEDIATRIC IMMUNIZATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BONDED SYRINGE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BONDED SYRINGE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BONDED SYRINGE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BONDED SYRINGE MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BONDED SYRINGE MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BONDED SYRINGE MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BONDED SYRINGE MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BONDED SYRINGE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BONDED SYRINGE MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BONDED SYRINGE MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BONDED SYRINGE MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BONDED SYRINGE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BONDED SYRINGE MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BONDED SYRINGE MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BONDED SYRINGE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BONDED SYRINGE MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BONDED SYRINGE MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BONDED SYRINGE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BONDED SYRINGE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL BONDED SYRINGE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 140. GCC BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. GCC BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 145. GCC BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. G7 BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 167. G7 BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 169. G7 BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 172. NATO BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 175. NATO BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 177. NATO BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL BONDED SYRINGE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA BONDED SYRINGE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA BONDED SYRINGE MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA BONDED SYRINGE MARKET SIZE, BY MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA BONDED SYRINGE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA BONDED SYRINGE MARKET SIZE, BY VACCINATION, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA BONDED SYRINGE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BONDED SYRINGE MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BONDED SYRINGE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)